Clinical trials
Phase 2 Diabetic Retinopathy trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
73 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2002 | 1 |
| 2003 | 1 |
| 2005 | 3 |
| 2006 | 4 |
| 2007 | 1 |
| 2008 | 8 |
| 2009 | 4 |
| 2010 | 2 |
| 2011 | 3 |
| 2012 | 2 |
| 2013 | 2 |
| 2015 | 3 |
| 2016 | 2 |
| 2017 | 3 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 5 |
| 2021 | 8 |
| 2022 | 4 |
| 2023 | 5 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 45 |
| Terminated | 8 |
| Unknown status | 8 |
| Active, not recruiting | 4 |
| Recruiting | 4 |
| Withdrawn | 2 |
| Not yet recruiting | 1 |
| Enrolling by invitation | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| University of Sao Paulo | 6 |
| Oxurion | 3 |
| ThromboGenics | 3 |
| AbbVie | 2 |
| Boehringer Ingelheim | 2 |
| National Eye Institute (NEI) | 2 |
| Novartis Pharmaceuticals | 2 |
| Pfizer | 2 |
| Quark Pharmaceuticals | 2 |
| Thomas Gardner | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Diabetic Retinopathy | 73 |
| Diabetes Mellitus | 22 |
| Macular Edema | 16 |
| Macular Degeneration | 6 |
| Retinal Diseases | 6 |
| Retinal Vein Occlusion | 5 |
| Blindness | 2 |
| Choroidal Neovascularization | 2 |
| Diabetes Mellitus, Type 2 | 2 |
| Edema | 2 |
Trials
Showing 1 to 25 of 73. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.